Abstracts tagged "tocilizumab and ultrasound"

Abstract Number: 558 • 2018 ACR/ARHP Annual Meeting
Major Reduction of Ultrasound Detected Synovitis during Subcutaneous Tocilizumab Treatment; Results from a Multicenter 24 Weeks Study of Patients with Rheumatoid Arthritis
Hilde B Hammer¹, Inger Marie Jensen Hansen², Pentti Järvinen³, Marjatta Leirisalo-Repo⁴, Michael Ziegelasch⁵, Birte Agular⁶ and Lene Terslev⁷, ¹Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Rheumatology, Svendborg Hospital, Svendborg, Denmark, ³Rheumatology, Kiljava Medical Research, Kiljavan, Finland, ⁴Rheumatology, University of Helsinki, Helsinki, Finland, ⁵Rheumatology, University Hospital, Linköping, Linköping, Sweden, ⁶Roche, Copenhagen, Denmark, ⁷Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Rigshospitalet, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Denmark
Background/Purpose: Ultrasound (US) is sensitive for detection of synovitis (assessed by Grey Scale (GS) and power/color Doppler). Presence of Doppler activity is found to predict…
Abstract Number: 2868 • 2018 ACR/ARHP Annual Meeting
Tender Joint Count May Not Reflect Inflammatory Activity in Established Rheumatoid Arthritis Patients; Results from a Longitudinal Study of Tocilizumab
Hilde B Hammer¹, Inger Marie Jensen Hansen², Pentti Järvinen³, Marjatta Leirisalo-Repo⁴, Michael Ziegelasch⁵, Birte Agular⁶ and Lene Terslev⁷, ¹Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Rheumatology, Svendborg Hospital, Svendborg, Denmark, ³Rheumatology, Kiljava Medical Research, Kiljavan, Finland, ⁴Rheumatology, University of Helsinki, Helsinki, Finland, ⁵Rheumatology, University Hospital, Linköping, Linköping, Sweden, ⁶Roche, Copenhagen, Denmark, ⁷Rheumatology, Rigshospitalet Glostrup, Copenhagen, Denmark
Background/Purpose: Tender joints may be caused by non-inflammatory pathologies but are still included in composite scores like CDAI. The present objective was to explore the…
Abstract Number: 129 • 2016 ACR/ARHP Annual Meeting
Ultrasound Is More Reliable Than Inflammatory Parameters (ESR and CRP) to Evaluate Disease Activity in Rheumatoid Arthritis Patients on Tocilizumab Therapy
Ying-Chou Chen Sr., Division of Rheumatology, Allergy and Immunology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan., YC Chen, Kaohsiung County, Taiwan
Background/Purpose: The goal of therapy of rheumatoid arthritis(RA) is to achieve a remission or at least low disease activity. Tocilizumab completely interrupt the effect of…
Abstract Number: 2604 • 2016 ACR/ARHP Annual Meeting
Ultrasound and Immunological Changes and Associations after One Year of IL-6/IL- 6R Blockade with Tocilizumab in Rheumatoid Arthritis Patients
Cesar Diaz-Torne¹, Juan Jose De Agustin², Patricia Moya¹, Maria A. Ortiz³, Delia Reina⁴, Carme Moragues⁵, Sergi Ros⁶, Emili Gomez⁷, Enrique Casado Burgos⁸, Eli Garcia⁹, Manel Pujol¹⁰, Maria Pilar Lisbona Perez¹¹, Andrés Ponce¹², V Torrente¹³, P. Estrada¹⁴, Silvia Vidal³ and ECOCAT group, ¹Rheumatology, Hospital Universitari de la Santa Creu i Sant Pau, Barcelona, Spain, ²Rheumatology, Hospital Baix de Llobregat, Barcelona, Spain, ³Institut de Recerca Sant Pau, Barcelona, Spain, ⁴Rheumatology, Hospital de Sant Joan Despí Moisès Broggi, Barcelona, Spain, ⁵Rheumatology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ⁶Rheumatology, Hospital de Viladecans, Viladecans, Spain, ⁷Rheumatology, Hospital Clínic, Barcelona, Spain, ⁸Hospital Universitari Parc Taulí, Sabadell, Spain, ⁹Rheumatology, Hospital de Mollet, Mollet, Spain, ¹⁰Hospital Mútua de Terrassa, Terrassa, Spain, ¹¹Rheumatology, Hospital de Sabadell, Sabadell, Spain, ¹²Rheumatology. Internal Medicine, Hospital General de Granollers, Granollers, Spain, ¹³Hospital de L'Hospitalet, L'Hospitalet de Llobregat, Spain, ¹⁴Rheumatology, Hospital Moises Broggi, Barcelona, Spain
Background/Purpose: Management of RA patients has improved in the last two decades in part with the use of ultrasound (US) in daily clinical practice. The…
Abstract Number: 470 • 2012 ACR/ARHP Annual Meeting
Concomitant Assessment of Clinical and Ultrasound Efficacy and Safety of Tocilizumab in Patients with Moderate to Severe Rheumatoid Arthritis: The Torpedo Study
Thierry Schaeverbeke¹, Philippe Gaudin², Aleth Perdriger³, Christian Roux⁴, Muriel Vray⁵, Stephanie Rouanet⁶, Ghislaine Steinberg⁷ and Fabien Etchepare⁸, ¹Service de Rhumatologie, Groupe Hospitalier Pellegrin, Bordeaux, France, ²Rheumatology Department, CHU Hôpital Sud, Grenoble Teaching Hospital, Echirolles, France, ³Rheumatology, Hôpital Sud, Rennes, France, ⁴Rheumatology, Paris Descartes University, Paris, France, ⁵Institut Pasteur, Paris, France, ⁶Medical Department, Roche, Boulogne, France, ⁷Medical department, Roche, Boulogne, France, ⁸G.H. Pitié-Salpêtrière, Paris, France
Background/Purpose: The anti-IL6-R tocilizumab (TCZ), indicated for the treatment of moderate to severe rheumatoid arthritis (RA), has demonstrated its clinical and structural efficacy in phase…
Abstract Number: 466 • 2012 ACR/ARHP Annual Meeting
Synovialitis Plus Articular Cartilage Monitoring Via Magnetic Resonance Imaging and Ultrasound Under Tocilizumab Therapy in Patients with Rheumatoid Arthritis
Maria Hoehle¹ and Michael Finkenstaedt², ¹Rheumatology, Hamburg, Germany, ²Private Practice for Radiology and Neuroradiology, Hamburg, Germany
Background/Purpose: To determine remission in RA, recent publications point out the importance of radiological parameters, besides scores like DAS28, TJC, SJC, CrP, patient global assessment,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].